Vicuron Provides Update on Novartis Peptide Deformylase Inhibitor Program

Vicuron Pharmaceuticals has received another milestone payment from Novartis Pharma AG in recognition of follow-up lead product candidates identified for Novartis' development from its ongoing research collaboration focused on peptide deformylase inhibitors, a novel class of antibiotics.

The company also announced that Novartis has suspended Phase I development of the first lead product candidate from the outpatient respiratory tract program in favor of developing a second lead compound, which is expected to enter the clinic by the end of the year.